News & Press

Suneva Medical Announces Positive Interim Data

May 30, 2013

Suneva Medical Announces Positive Interim Data from Five-Year Safety and Patient Satisfaction Study on Artefill® – Study Suggests Artefill Is As Safe as Other Dermal Fillers for Nasolabial Fold Correction – – Data Presented at Maui Derm 2010 Meeting – MAUI, HAWAII — January 25, 2010 – Suneva Medical, a privately-held aesthetic medical device company, …

Suneva Medical Announces Positive Interim Data Read More »

Two Studies Find Artefill® to Be a Long-Term Treatment

May 30, 2013

Two Studies Find Artefill® to Be a Long-Term Treatment Option for Facial Lipoatrophy Investigator-Initiated Studies Examine Artefill’s Use with Age-Related and HIV-Associated Facial Lipoatophy Patients SAN DIEGO, CA – February 2, 2010 – Suneva Medical, a privately-held aesthetic medical device company, today announced that two clinical studies suggest Artefill may be a safe, effective, long-term …

Two Studies Find Artefill® to Be a Long-Term Treatment Read More »

Leading U.S. Dermatologist Reports Positive Data on Artefill®

May 30, 2013

Leading U.S. Dermatologist Reports Positive Data on Artefill® Dr. Christopher Zachary Discusses Interim Data from Artefill Five-Year Safety and Patient Satisfaction Study at the Hawaii Dermatology Seminar SAN DIEGO, CA – February 16, 2010 – Suneva Medical, a privately-held aesthetic medical device company, today announced that Christopher B. Zachary, MBBS, FRCP, Professor and Chair, Department …

Leading U.S. Dermatologist Reports Positive Data on Artefill® Read More »

Leading Plastic Surgeons Report Positive Data on Artefill® at Key Society Meetings

May 30, 2013

Leading Plastic Surgeons Report Positive Data on Artefill® at Key Society Meetings SAN DIEGO, CA – May 4, 2010 – Suneva Medical, a privately-held aesthetic medical device company, today announced that Steven R. Cohen, M.D., F.A.C.S, Clinical Professor, University of California, San Diego and John H. Joseph, M.D., F.A.C.S, Assistant Clinical Professor, UCLA, presented interim …

Leading Plastic Surgeons Report Positive Data on Artefill® at Key Society Meetings Read More »

Suneva Medical Announces Publication of ArteFill® Five-Year Safety

May 30, 2013

Suneva Medical Announces Publication of ArteFill® Five-Year Safety and Patient Satisfaction Study Interim Results in Dermatologic Surgery SAN DIEGO, CA – May 5, 2010 – Suneva Medical, a privately-held aesthetic medical device company, today announced the publication of interim results from its long-term study on ArteFill in the May 2010 issue of Dermatologic Surgery, the …

Suneva Medical Announces Publication of ArteFill® Five-Year Safety Read More »

New Study Published in Journal of Drugs in Dermatology

February 14, 2019

New Study Published in Journal of Drugs in Dermatology Finds Artefill Effective in Treating Atrophic Acne Scars Ninety-Six Percent of Acne Scars Noticeably Improved Over Eight-Month Period SAN DIEGO, CA – October 7, 2010 – Suneva Medical, a privately-held aesthetic medical device company, today announced the publication of an open-label, single center, pilot study on …

New Study Published in Journal of Drugs in Dermatology Read More »

Important Safety Information

Bellafill®
Bellafill® is indicated for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. Patients who have had a positive reaction to the Bellafill® Skin Test, have a history of severe allergies, have known bovine collagen allergies, are allergic to lidocaine, have bleeding disorders or are prone to thick scar formation and/or excessive scarring should not receive Bellafill®. The safety of Bellafill® for use during pregnancy, breastfeeding, or in patients under 21 has not been established. You may experience temporary swelling, redness, pain, bruising, lumps/bumps, itching, and discoloration at the treatment site. These side effects are usually transient and typically resolve within 1–7 days. You may experience lumps/bumps/papules that may occur more than one month after injection and that may persist. Less common side effects include rash and itching more than 48 hours after treatment, persistent swelling or redness, lumps/bumps, acne, and increased sensitivity at treatment sites. Infrequently, granulomas may occur and may be treated by your licensed physician provider. Be sure to call your licensed provider immediately if you notice any unusual skin reactions around the treatment area. Based on the 5-year Post-Approval Study on nasolabial folds with 1,008 patients, long-term safety of Bellafill® for up to 5 years has been established.

PUREGRAFT
This product is certified as a medical device in the European Union under the Medical Device Directive 93/42/EEC by SGS CE0120, exclusively for the indication of autologous fat transfer. Other non-medical uses ascribed to this device such as aesthetic body contouring are not within the scope of CE certification, and users should be aware product performance and/or safety has not been evaluated by SGS for those purposes.

Suneva Medical HD PRP
REGULATORY STATUS: FDA-cleared 510(k) Class II medical device. Healeon HD PRP is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of peripheral blood at the patient point of care. The PRP is mixed with autograft and/orallograft bone prior to application to a bony defect for improving handling characteristics. 510(k) number: BK170136

Silhouette Instalift
Silhouette lnstaLift® is indicated for use in mid-face suspension surgery to temporarily fixate the cheek sub-dermis in an elevated position.

IMPORTANT SAFETY CONSIDERATIONS
The Silhouette InstaLift device should not be used in patients with any known allergy or foreign body sensitivities to plastic/ biomaterial or in situations where internal fixation is otherwise contraindicated, (e.g. infection.) The device should also not be used in patients appearing to have very thin soft tissue of the face in which the implant may be visible or palpable.

Like all procedures of this type there is a possibility of adverse events, although not everybody experiences them. These adverse events include but are not limited to infection, minimal acute inflammatory tissue reaction, pain (which may be temporary or persistent in nature), swelling and edema, transient hematoma or bruising and transient rippling or dimple formation. For further safety or product information, please consult your physician.

For more safety information, please consult with your physician and the patient labeling that can be found by visiting our website www.bellafill.com.
Toll-free call (U.S. & Canada): 844-Bellafill (844-235-5234).
Local calls: 858-550-9999. International calls: ++ 858-550-9999.